恩格列净联合二甲双胍治疗2型糖尿病的效果

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (633 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Empagliflozin combined with Metformin on patients with type 2 diabetes mellitus (T2DM). Methods A total of 200 T2DM patients admitted to the Department of Endocrinology of the Handan First Hospital, Hebei Province from November 2018 to February 2020, and they were divided into control group and observation group according to the random number table method, with 100 cases in each group. Among them, the control group was given Metformin, and the observation group was given Enggliazin combined with Metformin, and the treatment course was 12 months. After treatment, glucose metabolism indexes, cardiac ultrasound detection indexes, body weight, mean arterial pressure, sodium ion, and serum uric acid levels were compared between the two groups, and the occurrence of adverse reactions during treatment was recorded. Results After treatment, the levels of fasting blood glucose, 2 hours postprandial blood glucose, and glycosylated hemoglobin in two groups were lower than before, and the observation group was lower than the control group (P ＜ 0.05). After treatment, the E peak, LVEF, and LV mass index in the two groups were decreased, but the observation group was better than those of the control group (P ＜ 0.05). After treatment, body weight, mean arterial pressure, sodium ion, and serum uric acid levels in two groups were lower than before, and observation group was lower than those of control group (P ＜ 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups after treatment (P ＞ 0.05). Conclusion Enpagliflozin combined with Metformin in the treatment of T2DM can improve the patient’s blood glucose control, and by regulating the patient’s blood sugar, reducing the patient’s body weight, serum uric acid, maintaining blood pressure, and sodiumion levels, and protecting the cardiovascular system of T2DM patients.

Key words： Enpagliflozin Type 2 diabetes mellitus Cardiovascular Mechanism of action

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	NIU Shangmei1 SONG Xiaomeng1 ZHANG Xiaojie1 YANG Yingtao2 GUO Huijun2 HAN Shichao1

Cite this article:

NIU Shangmei1 SONG Xiaomeng1 ZHANG Xiaojie1 YANG Yingtao2 GUO Huijun2 HAN Shichao1. Effiect of Enpagliflozin combined with Metformin in the treatment of type 2 diabetes mellitus#br#[J]. 中国医药导报, 2022, 19(6): 76-80.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I6/76

[1] 苏工，高明喜，杨红霞.2020年美国心脏病学会《降低2型糖尿病患者心血管风险新型疗法的专家共识决策路径》解读：降糖更要护心[J].中国全科医学，2021，24（5）：509-516.
[2] 贺小宁，张雅雯，阮贞，等.中国2型糖尿病患者慢性并发症患病率与次均医疗费用研究[J].中华内分泌代谢杂志，2019，35（3）：200-205.
[3] 刘思默，柯静，赵冬.钠-葡萄糖协同转运蛋白2抑制剂改善2型糖尿病患者心血管结局的机制探讨[J].中华糖尿病杂志，2021，13（1）：103-106.
[4] 李琳，李全民.钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的机制研究进展[J].中华糖尿病杂志，2018，10（6）：430-433.
[5] 宋艳东，李志忠，张京梅，等.钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者的心血管保护作用[J].中国医药，2019，14（11）：1746-1749.
[6] 彭湾湾，薛君力.恩格列净联合胰岛素强化治疗肥胖2型糖尿病患者的疗效与安全性[J].实用医学杂志，2019，35（20）：3223-3226.
[7] 潘玲云，唐学文，田晓江，等.钠-葡萄糖共转运蛋白2抑制剂上市后安全信号的检测与分析[J].中华糖尿病杂志，2019，11（4）：248-253.
[8] Wiviott SD，Raz I，Bonaca MP，et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes [J]. N Engl J Med，2019，380（4）：347-357.
[9] Bhatt DL，Szarek M，Steg PG，et al. SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J]. N Engl J Med，2021， 384（2）：117-128.
[10] Cannon CP，Pratley R，Dagogo-Jack S，et al. VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes [J]. N Engl J Med，2020，383（15）：1425-1435.
[11] Ingelfinger JR，Rosen CJ. Clinical Credence - SGLT2 Inhibitors，Diabetes，and Chronic Kidney Disease [J]. N Engl J Med，2019，380（24）：2371-2373.
[12] 中华医学会糖尿病学分会.中国2型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[13] Henning RJ. Type-2 diabetes mellitus and cardiovascular disease [J]. Future Cardiol，2018，14（6）：491-509.
[14] Zelniker TA，Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors：JACC State-of-the-Art Review [J]. J Am Coll Cardiol，2020，75（4）：422-434.
[15] Heerspink HJ，Perkins BA，Fitchett DH，et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus：Cardiovascular and Kidney Effects，Potential Mechanisms，and Clinical Applications [J]. Circulation，2016，134（10）：752-772.
[16] Filion KB，Lix LM，Yu OH，et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events： multi-database retrospective cohort study [J]. BMJ，2020，370（1）：m3342.
[17] Lytvyn Y，Bjornstad P，Udell JA，et al. Response by Lytvyn et al to Letter Regarding Article，“Sodium Glucose Cotransporter-2 Inhibition in Heart Failure：Potential Mechanisms，Clinical Applications，and Summary of Clinical Trials” [J]. Circulation，2018，137（18）：1984-1985.
[18] Jarcho JA. More Evidence for SGLT2 Inhibitors in Heart Failure [J]. N Engl J Med，2020，383（15）：1481-1482.
[19] Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus [J]. Indian Heart J，2018，70（6）：915-921.
[20] 关泽勇，王立立.冠心病病人血清尿酸水平与冠状动脉病变稳定性，内皮功能及侧支循环形成的关系探讨[J].中西医结合心脑血管病杂志，2020，18（8）：1259-1262.
[21] 吴易航，张宇辉，张健.SGLT2i恩格列净对2型糖尿病患者心脏保护作用的研究进展[J].心血管病学进展，2020，225（8）：5-7，47.
[22] 张文君，孙文早，胡绍波，等.恩格列净、利拉鲁肽与二甲双胍治疗新发2型糖尿病合并非酒精性脂肪肝的临床疗效及对血清炎性因子、D-二聚体及肝功能的影响[J].临床和实验医学杂志，2021，20（8）：834-838.
[23] 刘红丹，范静.恩格列净治疗2型糖尿病肾病的临床观察[J].中国当代医药，2021，28（14）：84-88.
[24] Ingelfinger JR，Rosen CJ. Clinical Credence-SGLT2 Inhibitors，Diabetes，and Chronic Kidney Disease [J]. N Engl J Med，2019，380（24）：2371-2373.
[25] Zhang XL，Zhu QQ，Chen YH，et al. Cardiovascular Safety，Long-Term Noncardiovascular Safety，and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus： A Systemic Review and Meta-Analysis With Trial Sequential Analysis [J]. J Am Heart Assoc，2018，7（2）：1321.
[26] Lopaschuk GD，Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 （SGLT2） Inhibitors：A State-of-the-Art Review [J]. JACC Basic Transl Sci，2020，5（6）：632-644.
[27] Woo VC. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes [J]. Can J Diabetes，2020，44（1）：61-67.
[28] Levine MJ. Empagliflozin for Type 2 Diabetes Mellitus： An Overview of Phase 3 Clinical Trials [J]. Curr Diabetes Rev，2017，13（4）：405-423.